QSP Platform for Predicting Alternate Priming Dose, Efficacy, and CRS Incidence in CD3 Bispecifics for STEAP1 Prostate Cancer

A quantitative systems pharmacology (QSP) model framework for combined clinical efficacy and hematological toxicity predictions for antibody-drug conjugates

DEVELOPMENT OF QSP PLATFORM MODEL FOR PREDICTING ALTERNATE PRIMING DOSE

A comprehensive multi-scale in silico approach for predicting antibody-drug conjugate clinical efficacy across oncological indications

A quantitative systems pharmacology (QSP) model for predicting the efficacy

CLINICAL DOSE PREDICTION FOR CHIMERIC ANTIGEN RECEPTOR

Development of Immuno-Oncology (IO) QSP Platform

QSP Model of Rheumatoid Arthritis

Development of mPBPK-target engagement model

A Bootstrapping Method to Optimize

Supporting dose decisions for Antibody Drug Conjugates

Does Progressive Disease Justify Pembrolizumab discontinuation